Skip to main content

Table 1 Patient characteristics

From: The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study

  Mitiglinide Glimepiride
n (M/F) 15 (10/5) 7 (6/1)
Age, years 58.5 ± 11.5 65.1 ± 7.5
BMI, kg/m2 24.8 ± 4.0 26.3 ± 6.2
SBP, mmHg 137 ± 17 132 ± 20
DBP, mmHg 80 ± 7 79 ± 11
Total cholesterol, mmol/L 5.38 ± 0.98 5.43 ± 1.08
(mg/dL) (208 ± 38) (210 ± 42)
Triglycerides, mmol/L 1.71 ± 1.14 1.89 ± 0.74
(mg/dL) (152 ± 101) (168 ± 66)
HDL-C, mmol/L 1.39 ± 0.38 1.37 ± 0.31
(mg/dL) (54 ± 15) (53 ± 12)
Fasting glucose, mmol/L 6.88 ± 1.27 8.16 ± 1.05
(mg/dL) (124 ± 23) (147 ± 19)
2-h postload glucose, mmol/L 9.11 ± 1.94 11.6 ± 1.77
(mg/dL) (164 ± 35) (209 ± 32)
HbA1c(NGSP),% 6.80 ± 0.54 7.60 ± 0.63
Fasting IRI, pmol/L 52.7 ± 53.4 49.3 ± 36.1
(ng/mL) (7.6 ± 7.7) (7.1 ± 5.2)
HOMA-R 2.55 ± 3.10 2.67 ± 2.09
ISI (Matsuda’s index) 7.73 ± 3.16 7.68 ± 4.69
Insulinogenic index 0.80 ± 0.61 0.42 ± 0.38
CPR, nmol/L 0.59 ± 0.30 0.57 ± 0.17
(ng/mL) (1.79 ± 0.93) (1.72 ± 0.51)
Proinsulin, pmol/L 4.29 ± 4.16 4.77 ± 4.04
PI/I ratio 0.10 ± 0.11 0.19 ± 0.26
  1. Data are means ± standard deviation.
  2. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; IRI, immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; CPR, C-peptide immunoreactivity; PI/I ratio, proinsulin/insulin ratio.